By John Vandermosten, CFA NASDAQ:LEXX READ THE FULL LEXX RESEARCH REPORT Lexaria Bioscience Corporation (NASDAQ:LEXX) reported fiscal second quarter 2025 results through the filing of its Form 10-Q. Since our previous update, the company has made progress with its multiple GLP-1 trials, received patent awards in epilepsy and shared its strategy for advancing its development … Read more
NASDAQ:SNGX David Bautz: Hi, everyone, and welcome to the next episode of our CEO Fireside Chats. My name is David Bautz and I’m a senior biotechnology analyst here at Zacks Small Cap Research. Joining me today is Chris Schaber. He is the Chief Executive Officer of Soligenix, Inc. They are a late-stage biopharmaceutical company focused … Read more
By M. Marin NASDAQ:NVX READ THE FULL NVX RESEARCH REPORT ‘Synergistic’ operating units complement one another as company advances strategy Technology company Novonix (NASDAQ:NVX) is developing a local battery materials supply chain for North America. Tariffs and international trade prospects shine a light, we believe, on the need for an onshore supply chain to support … Read more
By David Bautz, PhD NASDAQ:MTVA READ THE FULL MTVA RESEARCH REPORT Business Update Positive Phase 1 MAD Data for DA-1726 On April 15, 2025, MetaVia Inc. (NASDAQ:MTVA) announced positive results from the Phase 1 Part 2 multiple ascending dose (MAD) trial of DA-1726 in obesity. The results showed that the cohort receiving 32 mg of … Read more
By Thomas Kerr, CFA NASDAQ:NWTG READ THE FULL NWTG RESEARCH REPORT 4th Quarter 2024 Financial Results On March 31, 2025, Newton Golf Company (NASDAQ:NWTG) reported 4th quarter and full year 2024 financial results which show strong revenue growth and a substantial increase in gross margins. Revenues in the 4th quarter increased to $1.07 million, an … Read more